MedTrace Logo

GTP Regimen in the Treatment of Refractory/Recurrent HLH

NCT06038422 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2023-09-14

No results posted yet for this study

Summary

The goal of this clinical trial is to learn about efficacy and safety of GTP regimen in refractory/recurrent hemophagocytic lymphohistiocytosis. The main questions it aims to answer are:

* Overall remission rate of GTP regimen in R/R HLH
* Adverse effect of GTP regimen Participants will be treated with GTP regimen

Conditions

  • Refractory
  • Recurrence
  • Hemophagocytic Lymphohistiocytosis

Interventions

DRUG

GTP regimen

Refractory/recurrent hemophagocytic lymphohistiocytosis patients will be treated with GTP regimen (Emapalumab+Teniposide+Methylprednisolone)

Sponsors & Collaborators

  • Beijing Friendship Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Month
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-15
Primary Completion
2024-09-15
Completion
2025-09-15

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06038422 on ClinicalTrials.gov